Laboratory of Nanomedicine & Biomaterials, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Nanomedicine (Lond). 2010 Apr;5(3):361-8. doi: 10.2217/nnm.10.6.
The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation.
A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated.
Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs.
We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.
化疗与放疗的联合应用（同期放化疗）提高了局部肿瘤控制率和生存率。但由于其毒性高，应用受到限制。本研究报道了一种新的纳米颗粒（NP）治疗药物 ChemoRad NP，它可以提供生物靶向放化疗。
设计了一种可同时递送化疗药物和放疗药物的可生物降解的、生物相容的脂-聚合物杂化纳米颗粒。
我们以多西紫杉醇、铟-111 和钇-90 为模型药物，证明 ChemoRad NP 可以高效地包载化疗药物（最高可达 NP 重量的 9%）和放疗药物（每克 NP 携带 100mCi 的放射性同位素），并能有效地递送到靶部位。我们以前列腺癌为疾病模型，证明了 ChemoRad NP 的靶向递药能力和 ChemoRad NP 的更高治疗效果。
我们相信 ChemoRad NP 代表了一类新型治疗药物，有很大的潜力改善癌症治疗。
